{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}]}],"title":"QTcF interval for single beat <=450 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"QTcF interval for single beat > 450 to <= 480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"QTcF interval for single beat >480 to <=500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"QTcF interval for single beat > 500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67"}]}],"title":"QTcF interval for single beat increase from baseline <= 30 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"QTcF interval for single beat increase from baseline >30 to <= 60 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"QTcF interval for single beat increase from baseline > 60 msec"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"Criteria for QTcF interval for single beat were as follows, \\<= 450 msec, \\> 450 to \\<= 480 msec, \\> 480 to \\<=500 msec, \\> 500 msec, increase from baseline \\<= 30 msec, increase from baseline \\> 30 to \\<= 60 msec, increase from baseline \\> 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.","groups":[{"description":"Participants were randomized to receive vepdegestrant 200 milligrams (mg) orally, once daily on Days 1 to 28 of each 28-day cycle. Participants continued to receive assigned treatment until objective disease progression, unacceptable toxicity, death, participant refused further treatment, or one of the other reasons for treatment discontinuation per protocol was met.","id":"OG000","title":"Vepdegestrant (ARV-471)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"QTc substudy analysis set= subset of SAS participants in vepdegestrant (ARV-471) arm, randomized at selected sites and had ECG measurements to evaluate effect of ARV-471 on QTcF via serial triplicate ECGs (centrally read), had baseline ECG measurement (Cycle 1 Day 1 pre-dose) and at least one ECG measurement on Day 1 of Cycle 2 or Cycle 3 following \\>= 7 consecutive days of 200 mg ARV-471. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline and from the first dose of study treatment up to the end of treatment (EOT) i.e., 28 days after last dose of study treatment (approximately up to 19.56 months)","title":"Number of Participants According to Categorization of QT Interval Corrected Using Fridericia's Formula (QTcF) Results-QTc Substudy Analysis Set","type":"SECONDARY","unitOfMeasure":"Participants"}